Drug developer Servier’s brain cancer drug dramatically slows tumor progression


(Reuters) – Private drug developer Servier Group Inc said on Sunday its experimental brain cancer treatment had dramatically slowed the progression of a type of brain tumor, a positive for an area that has seen no progress in more than two decades.

The drug vorasidenib delayed the growth of grade 2 gliomas by a median of 27.7 months, more than double the 11.1 months seen in patients who received a placebo.

Grade 2 gliomas are progressive, malignant brain tumors that are more common in adults but can also occur in children and adolescents.

The study, involving 331 patients who had not received other treatments other than surgery, showed that vorasidenib significantly improved progression-free survival and delayed the time before further anticancer interventions, such as chemotherapy and radiation therapy, were performed. Also published in the New England Journal of Medicine.

Vorasidenib received Fast Track designation from the U.S. Food and Drug Administration (FDA) in March 2023, and the company is currently developing a timeline for submitting a vorasidenib New Drug Application (NDA) to the FDA.

The drug is part of France-based Servier’s acquisition of Agios Pharmaceuticals Inc’s cancer business for about $2 billion in 2020.

(Reporting by Juby Babu, Bengaluru, Editing by Angus MacSwan)


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button